Pradaxa Lawsuit

Pradaxa Lawsuit

The blockbuster blood-thinning drug Pradaxa has been linked to over 500 deaths and thousands of hemorrhages since it was first introduced to the market in 2010.

Talcum Powder Lawsuit

Talcum Powder Lawsuit

Studies have shown that the use of talcum powder increases a woman’s risk of developing ovarian cancer.

Often termed the “silent killer,” ovarian cancer is considered one of the most deadly cancers in women. It often develops without symptoms and is difficult to detect in its early stages, and thus frequently remains undiagnosed until it has metastasized, meaning it has spread to other organs.

Hip-Replacement Lawsuit

Hip-Replacement Lawsuit

It is estimated that over 500,000 people received metal-on-metal hip implants over the last 10 years in the U.S. alone. The dangers associated with these devices—which fail at an alarming rate—are well documented. The metal-on-metal movement inside the human body can cause the release of tiny metal particles, damaging the surrounding soft tissue and bone, and sometimes entering the bloodstream causing other systemic health issues. Failure often requires revision surgery to remove or replace the implant.

Morcellator Lawsuit

Morcellator Lawsuit

Johnson & Johnson has recalled a surgical tool that has been linked to spreading cancer in women undergoing hysterectomies for the treatment of fibroids.

Hip-Replacement Lawsuit

Actos Problems Lawsuit

Studies have shown that patients suffering from Type 2 diabetes who were prescribed Actos for over a year had two times the risk of bladder cancer than those diabetes patients not taking Actos.

Xarelto Lawsuit

Xarelto Blood Thinner Lawsuit

Widespread reports of injury are emerging from patients who have taken the blood-thinning drug Xarelto. The anticoagulant has been linked to severe and sometimes fatal bleeding events to which there is no antidote.

  • Tyco - $2.9B
  • DaimlerChrysler - $300M
  • Royal Dutch/Shell Transport - $450M
  • Pfizer - N/A
  • Abbott Labs - $1.6B
  • Toprol- $20M
  • GlaxoSmithKline - $1.04B
  • Genetically Modified Rice - $920M